Related Experiment Videos
[Permanent central venous catheters in oncologic patients]
M Schrøder1, I R Pedersen, R B Rasmussen
1Kirurgisk afdeling, Finseninstitutet, Rigshospitalet, København.
Ugeskrift for Laeger
|September 2, 1991
Summary
Permanent central venous catheters, including Hickman-Broviac (HB) and Port-a-Cath (PAC) systems, are crucial for cancer patients. Port-a-Cath showed a lower complication rate and reduced nursing care, making it preferable.
Area of Science:
- Oncology
- Vascular Surgery
- Medical Devices
Context:
- Permanent central venous catheters are vital for managing patients with malignancies.
- Two primary systems exist: Hickman-Broviac (HB) and the fully implantable Port-a-Cath (PAC).
- This study reviews their use at the Finsen Institute from 1984-1988.
Purpose:
- To compare the efficacy and complication rates of Hickman-Broviac catheters and Port-a-Cath systems in cancer patients.
- To evaluate the long-term performance and safety of these central venous access devices.
Summary:
- A total of 284 catheters (232 HB, 52 PAC) were inserted in 245 patients using the venous cut-down technique.
- Mean indwelling times were 99 days for HB and 92 days for PAC, with low sepsis and thrombosis rates.
- Port-a-Cath demonstrated a generally lower complication rate and reduced nursing care requirements compared to Hickman-Broviac.
Impact:
- The Port-a-Cath system offers a favorable safety profile and efficiency for long-term central venous access in oncology.
- The venous cut-down technique is suitable even for patients with coagulation disorders.
- Findings support the preference for Port-a-Cath in specific patient populations requiring permanent central venous access.